Loading patent…
AssigneeKowa Company, Ltd.
InventorsYasushi Saito, Ryozo Nagai, Masunori Matsuzaki, Takeshi Kimura, Hiroaki Shimokawa, Hiroyuki Daida, Satoshi Iimuro, Hiroshi Iwata, Yukio Ozaki, Ichiro Sakuma, Yoshihisa Nakagawa, Kiyoshi Hibi, Takafumi Hiro, Yoshihiro Fukumoto, Seiji Hokimoto, Katsumi Miyauchi, Yasuo Ohashi
Estimating the term…
Methods of further reducing cardiovascular risk in subjects with coronary artery disease on moderate intensity statins.
1) A method of preventing an adverse cardiovascular event in a subject on a dosage of 1 mg/day pitavastatin or a pharmaceutically acceptable salt thereof, wherein the subject has an LDL-C concentration less than 120 mg/dL, comprising increasing the dosage to 4 mg/day for a therapeutically effective period of time.
3) A method of preventing an adverse cardiovascular event in a subject with stable coronary artery disease, comprising administering to the subject 4 mg/day of pitavastatin or a pharmaceutically acceptable salt thereof for a therapeutically effective period of time.
5) A method of preventing an adverse cardiovascular event in a subject on a dosage of 1 mg/day pitavastatin or a pharmaceutically acceptable salt thereof, wherein the subject has stable coronary artery disease and an LDL-C concentration less than 120 mg/dL, comprising increasing the dosage to 4 mg/day for a therapeutically effective period of time.
6) (canceled)
7) (canceled)
9) (canceled)
10) (canceled)
11) (canceled)
12) (canceled)
13) (canceled)
14) (canceled)
15) (canceled)
16) (canceled)
17) (canceled)
18) (canceled)
19) (canceled)
20) (canceled)
21) (canceled)
22) (canceled)
24) (canceled)
26) (canceled)
27) (canceled)
28) (canceled)
30) (canceled)
32) (canceled)
33) (canceled)
34) (canceled)
36) (canceled)
37) (canceled)
38) (canceled)
39) (canceled)
41) (canceled)
42) (canceled)
43) (canceled)
44) (canceled)
45) (canceled)
46) (canceled)
48) (canceled)
50) (canceled)
52) (canceled)
Dependencies are inferred from the claim text.